UCT943 是新一代恶性疟原虫Plasmodium falciparumPI4K抑制剂。UCT943 抑制P. vivaxPI4K (PvPI4K) 酶,IC50为 23 nM。
生物活性 | UCT943 is a next-generationPlasmodiumfalciparumPI4Kinhibitor. UCT943 inhibits theP. vivaxPI4K(PvPI4K) enzyme with anIC50of 23 nM[1]. |
IC50& Target[1] | PvPI4K 23 nM (IC50) | Plasmodium |
|
体外研究 (In Vitro) | UCT943 maintains high in vitro selectivity (>200-fold) for the parasitePvPI4K versus the human PI4Kβ isozyme (IC50of PI4Kβ, 5.4 μM), inhibition of which is linked to immunosuppressive effects[1]. In vitro cytotoxicity of UCT943 is tested against L6 cells, chinese hamster ovarian (CHO), Vero, and HepG2 cells, with 50% cytotoxic concentrations (CC50s) of 12, 17, 113, and 13 μM, respectively[1].
|
体内研究 (In Vivo) | UCT943 shows excellent in vivo efficacy in thePlasmodium berghei(10 mg/kg and 3 mg/kg; oral administration; daily; 4 days) andP. falciparumNSG (NOD-scid IL-2Rγnull) mouse models (0.01, 0.1, 0.3, 1.1 and 10 mg/kg; oral administration; once per day; 4 days). When dosed at 10 mg/kgper os(p.o.), UCT943 reduces parasitemia by >99.9% in the mouseP. bergheiinfection model and cures all mice, with >30 mean survival days (MSD). At 3 mg/kg p.o., no complete cure is achieved, and MSD is 10 days, albeit parasitemia is reduced by 99%. The resulting 90% effective dose (ED90) is 1.0 mg/kg p.o. in theP. bergheiinfection model. The ED90is 0.25 mg/kg in theP. falciparum-infected NSG mouse model[1].
Animal Model: | Mice withP. bergheiandP. falciparumNOD-scid IL-2Rγnull(NSG) models[1] | Dosage: | 10 mg/kg and 3 mg/kg forP. bergheimodel; 0.01, 0.1, 0.3, 1.1 and 10 mg/kg forP. falciparumNOD-scid IL-2Rγnull(NSG) model | Administration: | Oral administration; daily; 4 days forP. bergheimodel Oral administration; once per day; 4 days forP. falciparumNOD-scid IL-2Rγnull(NSG) model | Result: | The ED90is 1.0 mg/kg in theP. bergheiinfection model. The ED90is 0.25 mg/kg in theP. falciparum-infected NSG mouse model. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 250 mg/mL(584.90 mM;Need ultrasonic) 配制储备液 1 mM | 2.3396 mL | 11.6981 mL | 23.3962 mL | 5 mM | 0.4679 mL | 2.3396 mL | 4.6792 mL | 10 mM | 0.2340 mL | 1.1698 mL | 2.3396 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.87 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.87 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.87 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|